THERAPY DOSSIER · th-cce6934a4b39

Farnesylthiosalicylic acid (FTS)

Drug · RAS inhibitor (INHIBITOR)

Evidence & regulatory context

Mechanism: RAS inhibitor (INHIBITOR)
Target: CHEMBL4524006
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL23293 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: Salirasib; FTS; Farnesylthiosalicylic acid
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00531401 ↗PHASE2completed

Salirasib for Treatment of Advanced Non-Small Cell Lung Cancer: a Phase II Study

Non-Small-Cell Lung Cancer

Enrolment: 71 · Results not recorded

NCT00867230 ↗PHASE1completed

Phase I Study of Farnesylthiosalicylic Acid (FTS) in Advanced Hematologic Malignancies

Myelodysplastic Syndrome · Leukemia

Enrolment: 18 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24704370 ↗2014Reported benefit

Ras regulates alveolar macrophage formation of CXC chemokines and neutrophil activation in streptococcal M1 protein-induced lung injury.

MouseOtherC57BL/6MaleBefore M1 protein challenge

Model: Streptococcus pyogenes M1 protein-induced acute lung injury

Ras inhibition with FTS reduced neutrophil recruitment, oedema formation and tissue damage in the lung, decreased neutrophil Mac-1 expression and abolished M1 protein-provoked CXC chemokine gene expression in alveolar macrophages.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…